TherapyNotes

TherapyNotes is a cloud practice-management and EHR platform built for behavioral health clinicians — psychologists, therapists, counsellors, social workers, and psychiatrists. The legal entity is TherapyNotes, LLC. Headquarters are in Horsham, Pennsylvania, with the original operations registered in Willow Grove (Crunchbase).

What they sell

A single integrated platform covering scheduling, electronic clinical notes, treatment planning, e-prescribing, electronic insurance claims, patient billing, secure messaging, telehealth, and a patient portal. The product is purpose-built for solo and small-group behavioral-health practices rather than large hospital systems — the wedge that separates TherapyNotes from horizontal EMRs like Epic or athenahealth and from broader-market behavioral-health systems like Qualifacts and Netsmart that target enterprise clinics (TherapyNotes website).

The platform handles insurance claims natively, including for out-of-network providers — an important detail in behavioral health, where a large share of clinicians do not contract with insurers and rely on superbill workflows (Practice of Therapy podcast).

Size and funding

TherapyNotes has never raised external capital. Tracxn classifies the company as "unfunded" with no investors, no acquisitions, and no investments listed as of March 2026 (Tracxn). Crunchbase records a single past job for Brad Pliner before TherapyNotes — Pliner Solutions, his prior IT consulting firm — with no PE or strategic investor on file (Crunchbase).

Annual revenue is reported at $21M by both RocketReach and Kona Equity (RocketReach; Kona Equity). Headcount estimates diverge: RocketReach lists 335 employees; Kona Equity lists ~124; Indeed places the company in the 201-500 band (Indeed). LinkedIn shows 91,605 followers, which is large for a company in this size band and suggests sustained organic reach into the clinician audience (LinkedIn). I take 335 as the working number for headcount and $21M as the working number for ARR, both at medium confidence pending audited disclosure or a Crunchbase verification — a BrightData lookup attempted on 2026-04-16 returned a token-expired error and could not confirm.

Founders and leadership

TherapyNotes was founded by Brad Pliner and his wife Dr. Debra Pliner. Dr. Debra Pliner is a clinical psychologist; Brad Pliner is a technologist with a Master's in Computer Science from Drexel University. Brad ran Pliner Solutions, a custom web-application and IT consulting firm specialising in healthcare clients, from 1996 to 2010. The company emerged from Brad building an electronic notes system for Debra's mental-health practice and recognising that smaller private practices had no purpose-built option (Practice of Therapy podcast; TherapyNotes "About" page).

Brad Pliner has been CEO since the 2010 founding — a continuous 16-year tenure as of April 2026, which lands him squarely inside the founder-tenure exit-signal window Rivas Will tracks: a founder who has held the CEO seat for more than 12 years. No public successor has been named and no Chairman or President title has been added to the cap table.

I found no current "VP Corporate Development", "Head of M&A", or "Head of Strategy" role posted at TherapyNotes as of April 2026 (Indeed Corp Dev VP search, filtered for TherapyNotes — no hits). Active hires on ZipRecruiter and Built In are product, engineering, and customer-success roles, not corporate-development positions (ZipRecruiter). Signal 3 (hiring) is therefore negative; Signal 4 (founder language) has not produced a public "next chapter" post that I can find.

Signal 3 re-verification, 2026-04-19 — dated null. The three discoverable Workable postings on apply.workable.com/therapynotes are Senior Database Site Reliability Engineer (posted 26 Mar 2026), Senior Quality Assurance Engineer (Automation), and Senior Software Developer (posted 7 Apr 2026) — all engineering. No VP Corporate Development, no Head of M&A, no Head of Strategy, no Chief of Staff (apply.workable.com/therapynotes/j/127FE35A05; apply.workable.com/therapynotes/j/2B5078BB2A).

Signal 4 re-verification, 2026-04-19 — dated null. Brad Pliner's LinkedIn headline still reads "CEO, TherapyNotes, LLC" (LinkedIn). No "next chapter" / "grateful" / "stepping down" public posts surface for him in open-web search. Crunchbase still lists him as CEO with "no recent news or activity for this profile."

Market position

The behavioral-health EHR market is structurally consolidating, but TherapyNotes is one of the very few independent operators of meaningful scale left. Mordor Intelligence pegs the global behavioral-health EHR market at $1.56B in 2025, projected to reach $2.74B by 2030 at an 11.87% CAGR (Private Markets Minute, citing Mordor Intelligence). The competitive set is dominated by PE-backed platforms:

• SimplePractice — Vista Equity Partners portfolio company; the largest direct competitor for solo and small-group practices ([Vista buyer brief](../buyers/vista-equity-partners.md)).
• Valant — Quad-C-backed; targets group practices and integrated behavioral-health organisations.
• Kipu Health — Level Equity-backed; substance-use and addiction-treatment focus.
• ICANotes — Sheridan Capital Partners completed its investment on 13 January 2026 (not April 2026, a date I previously had wrong); Jamie Morganstern is ICANotes CEO and Jeff Foote led for Sheridan. Financial terms not disclosed; the Sheridan press release does not itself use "roll-up" language, though Private Markets Minute characterises the deal as a platform play in behavioral-health EHR (Sheridan Capital press release; Private Markets Minute).
• Therapy Brands (Sigmund, Procentive, TheraNest) — KKR portfolio.
• Qualifacts — enterprise-tier; PE-backed, repeat consolidator.
• Netsmart Technologies — TPG / GI Partners; large integrated-care focus.
• Tebra (formerly Kareo + PatientPop) — Vista-backed.

Owler lists SimplePractice, MedEZ, and eMDs as the closest direct competitors to TherapyNotes (Owler). What stands out in the comp set is that every major competitor is PE-owned or PE-backed except TherapyNotes. In a market growing at 11.87% CAGR with eight or more roll-up platforms actively acquiring, an unfunded $21M-ARR independent with 16-year founder tenure is the definition of a known target.

Exit signals

Strength 2 of 5. The signal is founder tenure plus a fully-consolidated competitive set. There is no observed VP Corporate Development hire, no observed founder-language shift, and no public "process underway" rumour. But the structural pressure is high:

• Every adjacent buyer Rivas Will tracks in the sub-vertical (Vista, KKR, TPG, Quad-C, Level Equity, Sheridan, GI Partners) has either an active platform in behavioral-health EHR or a stated mandate that would absorb one.
• Sheridan's 13 January 2026 ICANotes investment lands adjacent to TherapyNotes in the same sub-vertical; if Sheridan or a peer sponsor starts programmatic add-ons, a $21M unfunded independent is the obvious year-one or year-two target.
• Brad and Debra Pliner appear to own 100% of the equity, which means a sale is a one-conversation decision rather than a board process.

What to watch

• A first hire titled "VP Corporate Development", "Chief Strategy Officer", or "Head of Corporate Development" at TherapyNotes — would move signal strength from 2 to 4.
• A first PE banker pitch surfacing in industry chatter (Houlihan Lokey, Raymond James, William Blair are the most likely advisors for a $21M-ARR vertical EHR sale).
• Any change in Brad Pliner's LinkedIn headline away from CEO, or Dr. Debra Pliner taking a public board seat at another organisation.
• Sheridan Capital's first ICANotes add-on — if it is a TherapyNotes-shaped target, the buyer demand becomes harder to ignore.
• Vista's SimplePractice making any "extend product line into psychiatry / e-prescribing" announcement, since TherapyNotes is the cleanest acquihire to do that.

2026-04-29 cycle-back TRAVERSE

Five-day cycle-back was scheduled in the 2026-04-19 brief and is five days overdue here because of the orchestrator outage that wiped 2026-04-23 to 2026-04-28. Three findings.

Signal 3 (hiring) re-verified negative — dated null streak now ~13 days. Pulled live from the Workable account JSON (apply.workable.com/api/v1/widget/accounts/therapynotes) on 2026-04-29. Five active postings, all engineering / IT / QA: Business Intelligence Developer (Development, posted 28 Apr 2026), GRC Engineer (IT, 20 Apr 2026), Senior Database Site Reliability Engineer (IT, 26 Mar 2026), Senior Quality Assurance Engineer (QA, 27 Mar 2026), Senior Software Developer (Development, 8 Apr 2026). Two postings are new since the 2026-04-19 re-verification — GRC Engineer and Business Intelligence Developer — both technical, neither corporate-development-shaped. No VP Corporate Development, no Head of M&A, no Head of Strategy, no Chief of Staff, no Investor Relations role. The 13-day dated null at a $21M-revenue, 16-year-founder, fully-PE-saturated competitive set is informative: a sell-side process built around an institutional process needs a corp-dev role to run it, and hiring that role is a 60-90-day lead time before the role can actually run a bake-off. The longer the dated null persists, the further out the earliest plausible institutional sale.

Signal 4 (founder posture) re-verified negative. Brad Pliner's LinkedIn headline still reads "CEO, TherapyNotes, LLC" per the 2026-04-29 SERP refresh (apply.workable.com/therapynotes account-level metadata also still shows the husband-and-wife founder framing). No "next chapter" / "stepping down" / "grateful" public posts on his profile. RocketReach still names him as CEO. No founder-side language shift.

Comp-set tuck-in pace at Sheridan / ICANotes — also dated null. Sheridan Capital's own news page, refetched 2026-04-29, runs through Q1 2026 and shows zero ICANotes add-ons since the 13 January 2026 platform investment. The most recent firm-wide post is the 27 January 2026 "2025 was a strong year" recap. By contrast, Sheridan's Currier Plastics platform (29 Sept 2025) had its first two add-ons (Springboard Manufacturing and MOS Plastics) within ~3.5 months on 8 January 2026; the Currier comp suggests Sheridan's typical platform-to-first-tuck-in cadence in industrials is fast. ICANotes is now ~3.5 months in with no public add-on, which is at the leading edge of that cadence rather than past it. The dated null does not say "Sheridan is not pursuing add-ons" — it says "the first one has not yet been announced." A first ICANotes add-on, if it surfaces against an unfunded $5–15M ARR independent in behavioral-health EHR, will materially compress the available comp-set scarcity premium for TherapyNotes.

Exit-signal strength held at 2/5 with sharper dated-null framing. The 2026-04-19 re-verification framed the position at 2/5 on founder tenure plus structural saturation; ten days of additional dated null on Signals 3, 4, and the Sheridan tuck-in pace do not move the rating but tighten the constraint on how soon an institutional process could plausibly start. Five days of further unsupervised time gone in the orchestrator outage costs nothing here because none of the watch-items had public events to react to; the cycle-back's main contribution is the dated-null measurement itself.

2026-05-01 cycle-back TRAVERSE

36-hour cycle-back from the 2026-04-29 entry, prompted by the parallel 2026-05-01T08:55Z discover cycle that added Sheridan Capital Partners to the buyer roster as the first lower-middle-market healthcare-IT-only buyer. Two new findings, neither sufficient on its own to push exit- signal strength from 2 to 4, both materially sharpening the dated-null framing.

One: TherapyNotes implemented a price increase effective 1 December 2025, announced 30 October 2025 (TherapyNotes blog). Solo Practice rate to $69/month; group / enterprise rate to $79 for the first clinician plus $50 for each additional. The blog frames it as "ensuring TherapyNotes remains your go-to practice management solution" with five 2025 product enhancements cited (Secondary Claim Submission, Automatic Payments, Outcome Measure expansion, Robust Work Schedules & Extra Availability, Dark Mode). Why this matters. A founder-led pricing increase 12-15 months ahead of a plausible institutional sale process is a textbook margin-optimisation tell — it tightens trailing-twelve-month gross margin and ARR multiples in advance of buyer diligence. It is not exclusive to exit prep (companies also raise prices for ordinary operating reasons), and the language in the blog post is product-justification rather than financial-engineering. So it adds a fractional signal, not a full one — call it 0.5 of a point on the way from 2 to 4. Combined with the 16-year founder tenure and the unfunded-cap-table fact, the read is "consistent with exit prep but not yet pinned to a specific event."

Two: Q1 2026 product cadence has not slowed. The TherapyNotes blog continues shipping incremental product updates through Q1 2026 — TherapySearch Practice Link / Edit Medications / NPP Update on 5 February 2026 (blog post) and a Maintenance Release 2026.02 with revenue-report and scheduling improvements. Independent of exit-prep framing, sustained product cadence inside a 16-year founder-led shop with no observed Corp Dev hire reads as the founders still operating the company on a build-rather-than-prepare-to-sell footing. This softens the pricing-update signal: a company doing serious exit prep typically slows feature work to harden the existing platform, and TherapyNotes is not visibly doing that. The two reads do not contradict each other so much as bracket the timing — Pliner pair raised prices in Q4 2025, kept shipping in Q1 2026, and shows no public Corp Dev hire. That is consistent with "exit window 12-24 months out, not 6-12 months out."

Sheridan / ICANotes competitive-pressure dated null held. Same primary-source check as the 2026-04-29 cycle-back: Sheridan's news page shows no ICANotes add-on disclosed since the 13 January 2026 platform investment, ~3.7 months in. The Currier Plastics comp (Sheridan platform, first two add-ons inside 3.5 months) puts ICANotes at the leading edge of Sheridan's typical pace rather than past it. The dated null persists.

Exit-signal strength held at 2/5 with sharper dated context. Founder tenure 16 years, fully-PE-saturated competitive set, price increase 1 Dec 2025 added as fractional pre-exit margin signal, sustained product cadence into Q1 2026, no Corp Dev hire, no founder-language shift. The matrix-shape consequence is unchanged: the TherapyNotes × Sheridan cell remains PROSPECT_NOT_READY (signal=2 < gate=4); a future dated event on either Signal 3 (Corp Dev hire) or Signal 4 (Pliner posture) is the unblock.

Next cycle-back trigger: any new TherapyNotes Workable posting that is not engineering / QA / IT (next check ~2026-05-15); first Sheridan ICANotes tuck-in disclosure (any date); any change in Brad Pliner's LinkedIn headline.